These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8874139)

  • 1. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity.
    Lundkvist J; Chai Z; Teheranian R; Hasanvan H; Bartfai T; Jenck F; Widmer U; Moreau JL
    Eur J Pharmacol; 1996 Aug; 309(2):195-200. PubMed ID: 8874139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticotropin-releasing factor receptor type 1 mediates stress-induced relapse to cocaine-conditioned place preference in rats.
    Lu L; Liu D; Ceng X
    Eur J Pharmacol; 2001 Mar; 415(2-3):203-8. PubMed ID: 11275000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.
    Chen YL; Mansbach RS; Winter SM; Brooks E; Collins J; Corman ML; Dunaiskis AR; Faraci WS; Gallaschun RJ; Schmidt A; Schulz DW
    J Med Chem; 1997 May; 40(11):1749-54. PubMed ID: 9171885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
    Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
    J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone.
    Griebel G; Perrault G; Sanger DJ
    Psychopharmacology (Berl); 1998 Jul; 138(1):55-66. PubMed ID: 9694527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.
    Arborelius L; Skelton KH; Thrivikraman KV; Plotsky PM; Schulz DW; Owens MJ
    J Pharmacol Exp Ther; 2000 Aug; 294(2):588-97. PubMed ID: 10900236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress.
    Gutman DA; Owens MJ; Skelton KH; Thrivikraman KV; Nemeroff CB
    J Pharmacol Exp Ther; 2003 Feb; 304(2):874-80. PubMed ID: 12538845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.
    Schulz DW; Mansbach RS; Sprouse J; Braselton JP; Collins J; Corman M; Dunaiskis A; Faraci S; Schmidt AW; Seeger T; Seymour P; Tingley FD; Winston EN; Chen YL; Heym J
    Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10477-82. PubMed ID: 8816826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat.
    Zorrilla EP; Valdez GR; Nozulak J; Koob GF; Markou A
    Brain Res; 2002 Oct; 952(2):188-99. PubMed ID: 12376179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
    J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor.
    Aso K; Kobayashi K; Mochizuki M; Kanzaki N; Sako Y; Yano T
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2365-71. PubMed ID: 21414781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.
    Chaki S; Nakazato A; Kennis L; Nakamura M; Mackie C; Sugiura M; Vinken P; Ashton D; Langlois X; Steckler T
    Eur J Pharmacol; 2004 Feb; 485(1-3):145-58. PubMed ID: 14757135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.
    Mansbach RS; Brooks EN; Chen YL
    Eur J Pharmacol; 1997 Mar; 323(1):21-6. PubMed ID: 9105872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups.
    Kehne JH; Coverdale S; McCloskey TC; Hoffman DC; Cassella JV
    Neuropharmacology; 2000 Jun; 39(8):1357-67. PubMed ID: 10818252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists.
    Arban R; Benedetti R; Bonanomi G; Capelli AM; Castiglioni E; Contini S; Degiorgis F; Di Felice P; Donati D; Fazzolari E; Gentile G; Marchionni C; Marchioro C; Messina F; Micheli F; Oliosi B; Pavone F; Pasquarello A; Perini B; Rinaldi M; Sabbatini FM; Vitulli G; Zarantonello P; Di Fabio R; St-Denis Y
    ChemMedChem; 2007 Apr; 2(4):528-40. PubMed ID: 17335099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors.
    Hummel M; Cummons T; Lu P; Mark L; Harrison JE; Kennedy JD; Whiteside GT
    Neuropharmacology; 2010 Sep; 59(3):160-6. PubMed ID: 20470804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alcohol in excess: CRF₁ receptors in the rat and mouse VTA and DRN.
    Hwa LS; Debold JF; Miczek KA
    Psychopharmacology (Berl); 2013 Jan; 225(2):313-27. PubMed ID: 22885872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2.
    Martínez V; Wang L; Rivier JE; Vale W; Taché Y
    J Pharmacol Exp Ther; 2002 May; 301(2):611-7. PubMed ID: 11961064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence.
    Lu L; Liu D; Ceng X; Ma L
    Eur J Neurosci; 2000 Dec; 12(12):4398-404. PubMed ID: 11122350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.